Back to Journals » Cancer Management and Research » Volume 13

Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]

Authors Song X , Chen D , Yuan M, Wang H , Wang Z

Received 5 January 2021

Accepted for publication 5 January 2021

Published 5 February 2021 Volume 2021:13 Pages 1135—1136

DOI https://doi.org/10.2147/CMAR.S300538



Song X, Chen D, Yuan M, Wang H, Wang Z. Cancer Manag. 2018;10:6677– 6683

On page 6677, Abstract, Results subheading, the median baseline PLR should be 136.1.

On page 6680, Results section, 2nd paragraph, the median baseline PLR should be 136.1.

On page 6680, the red curve should be PLR ≥ 136.1 and the blue cure should be PLR < 136.1. The COX analysis was not correct in the previous publication and it has been revised and shown below in the new Tables 1 and table 2.
The correct Figure 3 is shown below

On page 6680, Table 2, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 2 is shown below.

On page 6681, Table 3, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 3 is shown below.

The authors have advised errors were caused by carelessness and mis-operation in statistics.


The authors apologize for this error and advise it does not affect the results of the paper.

Read the original article

Creative Commons License © 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.